Patients'perspectives on smoking and inflammatory bowel disease:An online survey in collaboration with European Federation of Crohn's and Ulcerative Colitis Associations  

作　　者：Catherine Le Berre Laura Loy Sanna Lönnfors Luisa Avedano Daniele Piovani 

机构地区：[1]Institut des Maladies de l'Appareil Digestif,Nantes University Hospital,Nantes 44000,France [2]Department of Gastroenterology,Humanitas Clinical and Research Institute,Rozzano,Milan 20089,Italy [3]European Federation of Crohn's and Ulcerative Colitis Associations,Brussels B-1000,Belgium [4]Department of Biomedical Sciences,Humanitas University,Pieve Emanuele MI,Milan 20090,Italy [5]Humanitas Clinical and Research Center-IRCCS,Milan,Rozzano 20089,Italy

出　　处：《World Journal of Gastroenterology》2020年第29期4343-4355,共13页世界胃肠病学杂志（英文版）

基　　金：Supported by Philip Morris Products SA and coordinated by Linkt Health Ltd.

摘　　要：BACKGROUNDSmoking has detrimental effects on Crohn’s disease (CD) activity while data onulcerative colitis (UC) are conflicting. Little is known about the use and impact ofalternative smoking products in inflammatory bowel diseases (IBD).AIMTo understand the patients’ perceptions of the impact of smoking on their IBDand to assess differences between CD and UC patients.METHODSThe questionnaire was developed by Philip Morris Products SA in cooperationwith European Federation of Crohn's and Ulcerative Colitis Associations. Thefinal survey questionnaire consisted of 41 questions divided in 8 categories: (1)Subject screener;(2) Smoking history;(3) Background information;(4) IBD diseasebackground;(5) Current disease status;(6) Current therapeutics and medications;and (7) Current nicotine/cigarettes use and awareness of the impacts of smokingon IBD. The questionnaire was submitted online from 4th November 2019 to 11th March 2020 through the European Federation of Crohn's and Ulcerative ColitisAssociations website to IBD patients who were current smokers or had a historyof smoking.RESULTSIn total 1050 IBD patients speaking nine languages participated to the survey.Among them, 807 (76.9%) patients declared to have ever smoked or consumed analternative smoking product, with a higher proportion of current cigarettesmokers among CD patients (CD: 63.1% vs UC: 54.1%, P = 0.012). About twothirdsof the participants declared to have ever stopped cigarette smoking andrestarted (67.0%), with a significantly higher proportion among UC patientscompared to CD patients (73.1% vs 62.0%, P = 0.001). We also found significantdifferences between CD and UC patients in the awareness of the healthconsequences of smoking in their disease and in the perceived impact of smokingon disease activity, for both cigarettes and alternative smoking products.CONCLUSIONThis survey found significant differences between CD and UC patients in bothawareness and perception of the impact of smoking on their disease. Furtherefforts should be done to encourag

关 键 词：Inflammatory bowel disease Ulcerative colitis Crohn's disease Cigarettes Alternative smoking products TOBACCO NICOTINE Marijuana 

分 类 号：R574.62[医药卫生—消化系统] R163[医药卫生—内科学]